Info from the webinar last night - slides not.order. Valuation about US107m or AUD167m. Or about the equivalent of an AUD1.12/share offer.
148,558,232 shares on issue per the ASX website might be slightly more about 155m
https://www.asx.com.au/markets/company/rlt
Merged company initially about US600m marketcap if that's accurate with ebitda projections US300m + . Longterm ebitda multiple could be about x20 similar to Linde.. With about US60m in cash and US600m marketcapn dilution through to US300m + ebitda projections should be minimal.
Overall I think upside is reduced by merging but risks to execute through to Phase 2 reduced substantially..Still reasonable upside potential if about 86m shares in the combined ASP-Renergen..If US300m ebitda is reached x20 that a US6b marketcap or x10 from the initial US600m marketcap of the combined ASP-Renergen. Larger upside if ebitda outperforms and gets to US500m + etc.. Also would like to understand how much ebitda projections ASP is bringing to the table? Renergen projected R6b or US300m approx in ebitda projections alone in a Phase 2 guidance.
Info from the webinar last night - slides not.order. Valuation...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.040(3.57%) |
Mkt cap ! $32.75M | |||
| Open | High | Low | Value | Volume |
| $1.06 | $1.09 | $1.05 | $23.15K | 21.70K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4726 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 2214 | 1 |
View Market Depth
| Last trade - 15.57pm 13/06/2025 (20 minute delay) ? |
| RLT (ASX) Chart |